FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Warning Letter Issued to Meridian Bioscience

FDA sends a Warning Letter to Meridian Bioscience over serious quality system violations involving blood lead testing devices manufactured by its subs...

latest-news-card-1
Medical Devices

FDA Warns MAST Biosurgery Over Manufacturing Violations

FDA issues MAST Biosurgery a Warning Letter after an August inspection cited serious manufacturing quality and safety reporting violations related to ...

latest-news-card-1
Human Drugs

Drug Companies Using AI to Speed Submissions

Reuters reports that several drug companies say they are using artificial intelligence tools to speed up some of the time-intensive work needed for cl...

latest-news-card-1
Biologics

Scancell Advancing iSCIB1+ Into Phase 3 Melanoma Trial

FDA approves a Scancell Holdings IND to begin a registrational Phase 3 trial of iSCIB1+ in patients with advanced melanoma.

latest-news-card-1
Human Drugs

Former CytoDyn CEO Sentenced to Prison

A federal judge sentences former CytoDyn chief executive Nader Pourhassan to 30 months in prison for misleading investors about the development of an ...

latest-news-card-1
Human Drugs

FDA Cites Pine Pharma Over Sterility, Quality Control

FDA cites Pine Pharmaceuticals for multiple quality and sterility violations following a 10-day inspection of the companys drug outsourcing facility i...

latest-news-card-1
Human Drugs

Plausible Mechanism Drug Pathway Raises Process Concerns

A Health Affairs analysis on FDAs new pathway allowing drug approvals based on a plausible mechanism of action warns that the approach raises unresolv...

latest-news-card-1
Biologics

Sarepta Reports Positive Data on Duchenne Gene Therapy

Sarepta Therapeutics announces that its gene therapy Elevidys significantly slowed disease progression over three years in ambulatory patients with Du...

latest-news-card-1
Biologics

Advocacy Push Precedes FDA Meeting on Stalled Gene Therapy

AMT-130 is a gene therapy designed to lower levels of the mutant huntingtin protein believed to drive Huntingtons disease progression.

latest-news-card-1
FDA General

Symposium on Clinical Trials, Bioequivalence and Pharmacovigilance

U.S., U.K. and Canadian drug regulators announce a joint international symposium to discuss evolving regulatory expectations for clinical trials, bioe...